Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 471468, 15 pages
http://dx.doi.org/10.1155/2015/471468
Research Article

Cholesteryl Pullulan Encapsulated TNF-α Nanoparticles Are an Effective Mucosal Vaccine Adjuvant against Influenza Virus

R&D Center, Hayashibara Co. Ltd., 675-1 Fujisaki, Naka-ku, Okayama 702-8006, Japan

Received 22 May 2015; Revised 10 August 2015; Accepted 12 August 2015

Academic Editor: Leungwing Chu

Copyright © 2015 Daiki Nagatomo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Cherry, “The chronology of the 2002-2003 SARS mini pandemic,” Paediatric Respiratory Reviews, vol. 5, no. 4, pp. 262–269, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Michaelis, H. W. Doerr, and J. Cinatl Jr., “An influenza A H1N1 virus revival—pandemic H1N1/09 virus,” Infection, vol. 37, no. 5, pp. 381–389, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Kikuta, Y. Hirabayashi, T. Nagamine et al., “Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit,” Vaccine, vol. 8, no. 6, pp. 595–599, 1990. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Ichinohe, A. Kawaguchi, S.-I. Tamura et al., “Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge,” Microbes and Infection, vol. 9, no. 11, pp. 1333–1340, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Holmgren and C. Czerkinsky, “Mucosal immunity and vaccines,” Nature Medicine, vol. 11, supplement, pp. S45–S53, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Kiyono and S. Fukuyama, “Nalt-versus Peyer's-patch-mediated mucosal immunity,” Nature Reviews Immunology, vol. 4, no. 9, pp. 699–710, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Goodwin, C. Viboud, and L. Simonsen, “Antibody response to influenza vaccination in the elderly: a quantitative review,” Vaccine, vol. 24, no. 8, pp. 1159–1169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Garcon, G. Leroux-Roels, and W.-F. Cheng, “Vaccine adjuvants,” Perspectives in Vaccinology, vol. 1, no. 1, pp. 89–113, 2011. View at Publisher · View at Google Scholar
  9. E. De Gregorio, E. Caproni, and J. B. Ulmer, “Vaccine adjuvants: mode of action,” Frontiers in Immunology, vol. 4, article 214, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. B. B. Aggarwal, W. J. Kohr, P. E. Hass et al., “Human tumor necrosis factor: production, purification, and characterization,” The Journal of Biological Chemistry, vol. 260, no. 4, pp. 2345–2354, 1985. View at Google Scholar · View at Scopus
  11. H. Wajant, K. Pfizenmaier, and P. Scheurich, “Tumor necrosis factor signaling,” Cell Death and Differentiation, vol. 10, no. 1, pp. 45–65, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Calzascia, M. Pellegrini, H. Hall et al., “TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice,” The Journal of Clinical Investigation, vol. 117, no. 12, pp. 3833–3845, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Brunner, J. Seiderer, A. Schlamp et al., “Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo,” The Journal of Immunology, vol. 165, no. 11, pp. 6278–6286, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. Chen, H. Huang, T. Chang et al., “Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor,” Cancer Gene Therapy, vol. 9, no. 9, pp. 778–786, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Kayamuro, Y. Abe, Y. Yoshioka et al., “The use of a mutant TNF-α as a vaccine adjuvant for the induction of mucosal immune responses,” Biomaterials, vol. 30, no. 29, pp. 5869–5876, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Kayamuro, Y. Abe, Y. Yoshioka et al., “Mutant TNF-alpha, mTNF-K9o0R, is a novel candidate adjuvant for a mucosal vaccine against HIV,” Pharmazie, vol. 65, no. 4, pp. 254–256, 2010. View at Google Scholar
  17. V. D. Prajapati, G. K. Jani, and S. M. Khanda, “Pullulan: an exopolysaccharide and its various applications,” Carbohydrate Polymers, vol. 95, no. 1, pp. 540–549, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Akiyama, N. Morimoto, P. Kujawa, Y. Ozawa, F. M. Winnik, and K. Akiyoshi, “Self-assembled nanogels of cholesteryl-modified polysaccharides: effect of the polysaccharide structure on their association characteristics in the dilute and semidilute regimes,” Biomacromolecules, vol. 8, no. 8, pp. 2366–2373, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Akiyoshi, S. Kobayashi, S. Shichibe et al., “Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin,” Journal of Controlled Release, vol. 54, no. 3, pp. 313–320, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Akiyoshi, Y. Sasaki, and J. Sunamoto, “Molecular chaperone-like activity of hydrogel nanoparticles of hydrophobized pullulan: thermal stabilization with refolding of carbonic anhydrase B,” Bioconjugate Chemistry, vol. 10, no. 3, pp. 321–324, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Shimizu, T. Kishida, U. Hasegawa et al., “Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy,” Biochemical and Biophysical Research Communications, vol. 367, no. 2, pp. 330–335, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Kobiyama, T. Aoshi, H. Narita et al., “Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 8, pp. 3086–3091, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. K. T. Mody, A. Popat, D. Mahony, A. S. Cavallaro, C. Yu, and N. Mitter, “Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery,” Nanoscale, vol. 5, no. 12, pp. 5167–5179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Shiku, L. Wang, Y. Ikuta et al., “Development of a cancer vaccine: peptides, proteins, and DNA,” Cancer Chemotherapy and Pharmacology, vol. 46, no. 1, supplement, pp. S77–S82, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Kageyama, H. Wada, K. Muro et al., “Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients,” Journal of Translational Medicine, vol. 11, no. 1, article 246, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Kageyama, S. Kitano, M. Hirayama et al., “Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel,” Cancer Science, vol. 29, no. 3, pp. 601–607, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Fukuda, S. Ando, O. Sanou et al., “Simultaneous production of natural human tumor necrosis factor-α, -β and interferon-α from BALL-1 cells stimulated by HVJ,” Lymphokine Research, vol. 7, no. 2, pp. 175–185, 1988. View at Google Scholar
  28. M. A. Rodríguez-Monroy, S. Rojas-Hernández, and L. Moreno-Fierros, “Phenotypic and functional differences between lymphocytes from NALT and nasal passages of mice,” Scandinavian Journal of Immunology, vol. 65, no. 3, pp. 276–288, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. http://www.oecd.org/chemicalsafety/testing/oecdguidelinesforthetestingofchemicals.htm.
  30. H. Ayame, N. Morimoto, and K. Akiyoshi, “Self-assembled cationic nanogels for intracellular protein delivery,” Bioconjugate Chemistry, vol. 19, no. 4, pp. 882–890, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. H.-Y. Wu and M. W. Russell, “Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant,” Vaccine, vol. 16, no. 2-3, pp. 286–292, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Ichinohe, I. Watanabe, S. Ito et al., “Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection,” Journal of Virology, vol. 79, no. 5, pp. 2910–2919, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Muraoka, N. Harada, T. Hayashi et al., “Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity,” ACS Nano, vol. 8, no. 9, pp. 9209–9218, 2014. View at Publisher · View at Google Scholar
  34. M. O. Oyewumi, A. Kumar, and Z. Cui, “Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses,” Expert Review of Vaccines, vol. 9, no. 9, pp. 1095–1107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Patel, C. Yewale, M. Rathi, and A. Misra, “Mucosal immunization: a review of strategies and challenges,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 31, no. 4, pp. 273–303, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Yuki and H. Kiyono, “New generation of mucosal adjuvants for the induction of protective immunity,” Reviews in Medical Virology, vol. 13, no. 5, pp. 293–310, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Mestecky and J. R. McGhee, “Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response,” Advances in Immunology, vol. 40, pp. 153–245, 1987. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Mutsch, W. Zhou, P. Rhodes et al., “Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland,” The New England Journal of Medicine, vol. 350, no. 9, pp. 896–903, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. F. W. van Ginkel, R. J. Jackson, Y. Yuki, and J. R. McGhee, “Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues,” The Journal of Immunology, vol. 165, no. 9, pp. 4778–4782, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Onishi, K. Ozasa, K. Kobiyama et al., “Hydroxypropyl-β-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen,” The Journal of Immunology, vol. 194, no. 6, pp. 2673–2682, 2015. View at Publisher · View at Google Scholar
  41. V. M. Atger, M. de la Llera Moya, G. W. Stoudt, W. V. Rodrigueza, M. C. Phillips, and G. H. Rothblat, “Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells,” The Journal of Clinical Investigation, vol. 99, no. 4, pp. 773–780, 1997. View at Publisher · View at Google Scholar · View at Scopus